Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline

Programs Opioids Clinical Primer Resources Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline

Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline

Evidence, Guidelines and Recommendations

The objective of this guideline is to provide clinical recommendations for the initiation, maintenance and discontinuation of buprenorphine/naloxone maintenance treatment in the ambulatory treatment of adults and adolescents with opioid dependence in Ontario. Provided by the Centre for Addiction and Mental Health (CAMH) and the College of Physicians and Surgeons of Ontario (CPSO)

Details

Related Resources

Management of opioid use disorders: a national clinical practice guideline

This guideline was developed to provide Canadian health professionals with an educational tool and clinical practice recommendations for the treatment of opioid use disorder.

Visit

Learn more

Recommendations for the use of slow-release oral morphine as opioid agonist therapy

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).

Learn more

Safe Prescribing Practices for Addictive Medications and Management of Substance Use Disorders in Primary Care: A Pocket Reference for Primary Care Providers

Guidelines to Prescribing Addictive Medications developed by Women’s College Hospital for Primary Care Providers.

Download

Learn more